ICON Web & News
Search Using OECD Database
Return to Previous Page
Addition or Correction
Self-Assembled Graphene–Dextran Nanohybrid for Killing Drug-Resistant Cancer Cells
Link to Journal Abstract
A nanohybrid based on nanoscale graphene oxide (NGO) and dextran has been designed and employed for effectively killing drug-resistant MCF-7/ADR cells. This graphene-based nanohybrid was readily prepared through ð–ð interaction of NGO and hematin-terminated dextran (HDex), being denoted as NGO–HDex. It revealed an improved stability in physiological conditions as compared to native NGO. Besides, NGO–HDex could efficiently load doxorubicin (DOX), an anticancer drug, with drug loading capacity of 3.4 mg/mg NGO and liberate the drug with a pH-dependent profile. Cell viability assay indicated that the NGO–HDex displayed lower cytotoxicity against MCF-7/ADR cells as compared to native NGO. DOX-loaded NGO–HDex, however, revealed more efficient killing effect in the cells than free DOX because the nanohybrid caused a higher amount of DOX accumulated in the cells. The results of this study highlight that the NGO–HDex has high potential for killing drug-resistant cancer cell
For this study, a nanohybrid based on nanoscale graphene oxide (NGO) and dextran (denoted as NGO–HDex) was evaluated to determine effectiveness in killing drug-resistant MCF-7/ADR cells. Cell viability assay for the NGO–HDex was investigated to determine cytotoxicity against MCF-7/ADR cells as compared to native NGO.
Peer Reviewed Journal Article
Exposure Or Hazard Target
Method Of Study
Risk Exposure Group
ACS Applied Materials & Interfaces, 2013, 5(15): 7181-7189
ACS Applied Materials & Interfaces
Jin R, Ji X, Yang Y, Wang H, Cao A
Last updated on September 26, 2013
This work is supported in part by the Nanoscale Science and Engineering Initiative of the National Science Foundation
under NSF Award Number EEC-0118007.
Why Join Us?
Mission and Strategy
Good Nano Guide
Nano EHS Research Needs
Current Practices Survey